GEORGE G KLEE, M.D.
Medical Practice at 1 St, Rochester, MN
License number
Minnesota 22392
Category
Medical Practice
Type
Clinical Pathology/Laboratory Medicine
Address
Address
200 1St St SW, Rochester, MN 55905
Phone
(507) 284-2511
Professional information
George Gerald Klee, Rochester MN
Specialties:
Pathology, Clinical Pathology/Laboratory Medicine, Anatomic Pathology & Clinical Pathology, Clinical Pathology
Work:
Mayo Medical School
200 1St St Sw, Rochester, MN 55905
200 1St St Sw, Rochester, MN 55905
Education:
University of Minnesota, Twin Cities (1973)
George G Klee, Rochester MN
Specialties:
Pathologist
Address:
200 1St St Sw, Rochester, MN 55905
Education:
University of Minnesota, Medical School - Doctor of Medicine
The Mayo Clinic - Residency - Clinical Pathology
The Mayo Clinic - Residency - Clinical Pathology
Board certifications:
American Board of Pathology Certification in Clinical Pathology (Pathology)
Dr. George G Klee, Rochester MN - MD (Doctor of Medicine)
Specialties:
Clinical Pathology
Address:
Mayo Clinic
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
Certifications:
Clinical Pathology, 1977
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Mayo Clinic
200 1St St SW, Rochester 55905
Mayo Clinic Saint Marys Hospital
1216 2Nd St South #West, Rochester 55902
North Memorial Medical Center
3300 Oakdale Ave North, Robbinsdale 55422
200 1St St SW, Rochester 55905
Mayo Clinic Saint Marys Hospital
1216 2Nd St South #West, Rochester 55902
North Memorial Medical Center
3300 Oakdale Ave North, Robbinsdale 55422
Education:
Medical School
University Of Minnesota Medical School
Graduated: 1973
Mayo Grad School Med
Graduated: 1975
Graduated: 1977
University Of Minnesota Medical School
Graduated: 1973
Mayo Grad School Med
Graduated: 1975
Graduated: 1977
Method For Detection Of Breast Cancer
US Patent:
6235486, May 22, 2001
Filed:
Jun 19, 1998
Appl. No.:
9/100264
Inventors:
Charles Y. F. Young - Rochester MN
Donald J. Tindall - Rochester MN
George G. Klee - Rochester MN
Donald J. Tindall - Rochester MN
George G. Klee - Rochester MN
Assignee:
Mayo Foundation for Medical Education & Research - Rochester MN
International Classification:
G01N 3353
US Classification:
435 71
Abstract:
Breast cancer is detected by determining the presence of hK2 polypeptide or hK2 RNA in a physiological sample.
Clinical Assay Calibration Adjustment Method
US Patent:
6787361, Sep 7, 2004
Filed:
May 11, 2001
Appl. No.:
09/853867
Inventors:
George G. Klee - Rochester MN
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
G01N 3100
US Classification:
436 8, 436 43, 702 19, 702 22, 702 32
Abstract:
A method for calibrating a clinical laboratory analytical instrument that includes generating control pool data from a commutable control pool, wherein the control pools have target analyte values for an assay, generating patient specimen data from a distribution of test values from patient specimens, determining tolerance limits from the control pool data and the patient specimen data; and adjusting the calibration of the instrument with respect to the tolerance limits.
Methods Of Recovering Colorectal Epithelial Cells Or Fragments Thereof From Stool
US Patent:
5891651, Apr 6, 1999
Filed:
Mar 29, 1996
Appl. No.:
8/625015
Inventors:
Patrick C. Roche - Rochester MN
George G. Klee - Rochester MN
Paul J. Limburg - Rochester MN
David A. Ahlquist - Rochester MN
George G. Klee - Rochester MN
Paul J. Limburg - Rochester MN
David A. Ahlquist - Rochester MN
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
G01N 3353, G01N 33537, G01N 33541, G01N 33574
US Classification:
435 721
Abstract:
A method of recovering colorectal epithelial cells or fragments thereof from a stool sample is provided. The method involves contacting a stool sample with a specific binding reagent having specificity for colorectal epithelial cells or membrane fragments thereof to form a complex containing the specific binding reagent and the colorectal epithelial cells or fragments thereof, and separating the complex from the sample. A method of detecting dysplastic colorectal epithelial cells or fragments thereof, wherein a specific binding reagent employed in the method has specificity for dysplastic colorectal epithelial cells or membrane fragments thereof, is also provided. An article of manufacture containing reagents for performing the method is further provided.
Extracellular And Membrane-Associated Prostate Cancer Markers
US Patent:
8273539, Sep 25, 2012
Filed:
Sep 25, 2007
Appl. No.:
12/442685
Inventors:
George G. Klee - Rochester MN, US
George Vasmatzis - Byron MN, US
Farhad Kosari - Rochester MN, US
Eric W. Klee - Rochester MN, US
George Vasmatzis - Byron MN, US
Farhad Kosari - Rochester MN, US
Eric W. Klee - Rochester MN, US
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
G01N 33/53
US Classification:
435 71
Abstract:
This document relates to methods and materials involved in identifying, assessing, and monitoring prostate cancer in male mammals. For example, this document provides arrays for detecting polypeptides or nucleic acids that can be used to identify prostate cancer in male mammals. In addition, methods and materials for assessing and monitoring prostate cancer in mammals are provided herein.
Biomarker Panels For Predicting Prostate Cancer Outcomes
US Patent:
2009029, Dec 3, 2009
Filed:
May 29, 2009
Appl. No.:
12/474879
Inventors:
George G. Klee - Rochester MN, US
Robert B. Jenkins - Rochester MN, US
Thomas M. Kollmeyer - Rochester MN, US
Karla V. Ballman - Northfield MN, US
Eric J. Bergstralh - Mazeppa MN, US
Bruce W. Morlan - Northfield MN, US
S. Keith Anderson - Rochester MN, US
Tohru Nakagawa - Tokyo, JP
Robert B. Jenkins - Rochester MN, US
Thomas M. Kollmeyer - Rochester MN, US
Karla V. Ballman - Northfield MN, US
Eric J. Bergstralh - Mazeppa MN, US
Bruce W. Morlan - Northfield MN, US
S. Keith Anderson - Rochester MN, US
Tohru Nakagawa - Tokyo, JP
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
This document provides methods and materials related to assessing male mammals (e.g., humans) with prostate cancer. For example, methods and materials for predicting (1) which patients, at the time of PSA reoccurrence, will later develop systemic disease, (2) which patients, at the time of retropubic radial prostatectomy, will later develop systemic disease, and (3) which patients, at the time of systemic disease, will later die from prostate cancer are provided.
Extracellular And Membrane-Associated Prostate Cancer Markers
US Patent:
2013000, Jan 3, 2013
Filed:
Sep 7, 2012
Appl. No.:
13/607296
Inventors:
George G. Klee - Rochester MN, US
George Vasmatzis - Byron MN, US
Farhad Kosari - Rochester MN, US
Eric W. Klee - Rochester MN, US
George Vasmatzis - Byron MN, US
Farhad Kosari - Rochester MN, US
Eric W. Klee - Rochester MN, US
International Classification:
G01N 33/574
US Classification:
435 792
Abstract:
This document relates to methods and materials involved in identifying, assessing, and monitoring prostate cancer in male mammals. For example, this document provides arrays for detecting polypeptides or nucleic acids that can be used to identify prostate cancer in male mammals. In addition, methods and materials for assessing and monitoring prostate cancer in mammals are provided herein.
Antibodies Specific For Human Prostate Glandular Kallkrein
US Patent:
5516639, May 14, 1996
Filed:
Jul 22, 1993
Appl. No.:
8/096946
Inventors:
Donald J. Tindall - Rochester MN
Charles Y. F. Young - Rochester MN
George G. Klee - Rochester MN
Charles Y. F. Young - Rochester MN
George G. Klee - Rochester MN
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
G01N 33573
US Classification:
435 74
Abstract:
The present invention provides an isolated preparation of monoclonal or polyclonal antibodies which react specifically with human prostate-specific glandular kallikrein (hK2), but which do not cross-react with human prostate-specific antigen (PSA), as well as immunogenic hK2 antigens useful to provide such antibodies.